{"transactions":[{"id":841919,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-03-16T18:07:28.000Z","date":"2026-03-12","kind":"grant","planned":false,"acquired":true,"shares":80700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent of these options vest on March 12, 2027, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":80700,"derivative":{"exercise_price":0.765,"expiration_date":"2036-03-12","underlying":"Common Stock","underlying_shares":80700},"source":{"system":"sec-edgar","filing":"0001104659-26-028656","document":"tm268953-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465926028656/tm268953-2_4seq1.xml","form_type":"4"}},{"id":841918,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Stock","published_at":"2026-03-16T18:07:28.000Z","date":"2026-03-12","kind":"grant","planned":false,"acquired":true,"shares":20175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 12, 2027, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":393895,"source":{"system":"sec-edgar","filing":"0001104659-26-028656","document":"tm268953-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465926028656/tm268953-2_4seq1.xml","form_type":"4"}},{"id":925499,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Warrant","published_at":"2026-02-02T16:08:08.000Z","date":"2026-01-30","kind":"purchase","planned":false,"acquired":true,"shares":28100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the second year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Common Warrants are immediately exercisable, provided, that, the Common Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the second year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144."}],"balance_after":28100,"derivative":{"exercise_price":0.765,"exercise_date":"2026-01-30","underlying":"Common Stock","underlying_shares":28100},"source":{"system":"sec-edgar","filing":"0001104659-26-009206","document":"tm264801-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465926009206/tm264801-2_4seq1.xml","form_type":"4"}},{"id":925498,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Stock","published_at":"2026-02-02T16:08:08.000Z","date":"2026-01-30","kind":"purchase","planned":false,"acquired":true,"shares":28100,"price":0.89,"value":25009.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On January 28, 2026, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement, which closed on January 30, 2026, an aggregate of 28,100 shares of the Issuer's common stock (the \"Shares\") at a purchase price of $0.89 per Share. The Reporting Person also received accompanying common warrants (the \"Common Warrants\") to purchase up to an aggregate of 28,100 Shares."}],"balance_after":373720,"source":{"system":"sec-edgar","filing":"0001104659-26-009206","document":"tm264801-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465926009206/tm264801-2_4seq1.xml","form_type":"4"}},{"id":972789,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Warrants","published_at":"2025-12-11T08:30:14.000Z","date":"2025-12-10","kind":"purchase","planned":false,"acquired":true,"shares":21459,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"On December 8, 2025, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on December 10, 2025 pre-funded warrants (\"Pre-Funded Warrants\") to purchase an aggregate of 21,459 shares of the Issuer's common stock (\"Shares\") at a purchase price of $1.165 per Pre-Funded Warrant. The Reporting Person also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 21,459 Shares."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Common Warrants are immediately exercisable, subject to the Beneficial Ownership Limitation. The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the fifth year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Common Warrants are immediately exercisable, subject to the Beneficial Ownership Limitation. The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the fifth year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144."}],"balance_after":21459,"derivative":{"exercise_price":1.04,"exercise_date":"2025-12-10","underlying":"Common Stock","underlying_shares":21459},"source":{"system":"sec-edgar","filing":"0001104659-25-120152","document":"tm2533219-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465925120152/tm2533219-1_4seq1.xml","form_type":"4"}},{"id":972788,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Pre-Funded Warrant","published_at":"2025-12-11T08:30:14.000Z","date":"2025-12-10","kind":"purchase","planned":false,"acquired":true,"shares":21459,"price":1.165,"value":24999.735,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"On December 8, 2025, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on December 10, 2025 pre-funded warrants (\"Pre-Funded Warrants\") to purchase an aggregate of 21,459 shares of the Issuer's common stock (\"Shares\") at a purchase price of $1.165 per Pre-Funded Warrant. The Reporting Person also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 21,459 Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrants are immediately exercisable at any time after the date of issuance. Pursuant to the terms of the Pre-Funded Warrants, the Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise (the \"Beneficial Ownership Limitation\")"}],"balance_after":21459,"derivative":{"exercise_price":0.0001,"exercise_date":"2025-12-10","underlying":"Common Stock","underlying_shares":21459},"source":{"system":"sec-edgar","filing":"0001104659-25-120152","document":"tm2533219-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465925120152/tm2533219-1_4seq1.xml","form_type":"4"}},{"id":1177782,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Stock","published_at":"2025-04-04T07:30:11.000Z","date":"2025-04-03","kind":"purchase","planned":false,"acquired":true,"shares":2497,"price":1.8,"value":4494.6,"ownership":{"direct":true},"balance_after":345620,"source":{"system":"sec-edgar","filing":"0001104659-25-031991","document":"tm2511518-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465925031991/tm2511518-1_4seq1.xml","form_type":"4"}},{"id":1177781,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Stock","published_at":"2025-04-04T07:30:11.000Z","date":"2025-04-03","kind":"purchase","planned":false,"acquired":true,"shares":3003,"price":1.87,"value":5615.61,"ownership":{"direct":true},"balance_after":343123,"source":{"system":"sec-edgar","filing":"0001104659-25-031991","document":"tm2511518-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465925031991/tm2511518-1_4seq1.xml","form_type":"4"}},{"id":1188063,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2025-03-31T16:30:32.000Z","date":"2025-03-27","kind":"grant","planned":false,"acquired":true,"shares":26900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent of these options vest on March 27, 2026, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":26900,"derivative":{"exercise_price":2.2,"expiration_date":"2035-03-28","underlying":"Common Stock","underlying_shares":26900},"source":{"system":"sec-edgar","filing":"0001104659-25-029914","document":"tm2510809-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465925029914/tm2510809-1_4seq1.xml","form_type":"4"}},{"id":1188062,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Stock","published_at":"2025-03-31T16:30:32.000Z","date":"2025-03-27","kind":"grant","planned":false,"acquired":true,"shares":6725,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 27, 2026, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":340120,"source":{"system":"sec-edgar","filing":"0001104659-25-029914","document":"tm2510809-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465925029914/tm2510809-1_4seq1.xml","form_type":"4"}},{"id":1382025,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Stock","published_at":"2024-10-24T08:30:13.000Z","date":"2024-10-23","kind":"purchase","planned":false,"acquired":true,"shares":500,"price":3.915,"value":1957.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.91 to $3.92, inclusive. The reporting person undertakes to provide to the issuer or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":333395,"source":{"system":"sec-edgar","filing":"0001104659-24-111031","document":"tm2426748-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465924111031/tm2426748-1_4seq1.xml","form_type":"4"}},{"id":1385976,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Stock","published_at":"2024-10-16T08:31:25.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":250,"price":2.9,"value":725.0,"ownership":{"direct":true},"balance_after":332895,"source":{"system":"sec-edgar","filing":"0001104659-24-108964","document":"tm2426059-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465924108964/tm2426059-6_4seq1.xml","form_type":"4"}},{"id":1386782,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Stock","published_at":"2024-10-15T08:31:01.000Z","date":"2024-10-14","kind":"purchase","planned":false,"acquired":true,"shares":1000,"price":2.59,"value":2590.0,"ownership":{"direct":true},"balance_after":332645,"source":{"system":"sec-edgar","filing":"0001104659-24-108375","document":"tm2426059-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465924108375/tm2426059-3_4seq1.xml","form_type":"4"}},{"id":1386781,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President/CEO"}}],"security":"Common Stock","published_at":"2024-10-15T08:31:01.000Z","date":"2024-10-10","kind":"purchase","planned":false,"acquired":true,"shares":150,"price":2.54,"value":381.0,"ownership":{"direct":true},"balance_after":331645,"source":{"system":"sec-edgar","filing":"0001104659-24-108375","document":"tm2426059-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465924108375/tm2426059-3_4seq1.xml","form_type":"4"}},{"id":1558623,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2024-03-28T17:57:27.000Z","date":"2024-03-28","kind":"grant","planned":false,"acquired":true,"shares":26900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent of these options vest on March 28, 2025, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":26900,"derivative":{"exercise_price":6.69,"expiration_date":"2024-03-28","underlying":"Common Stock","underlying_shares":26900},"source":{"system":"sec-edgar","filing":"0001104659-24-040642","document":"tm2410009-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465924040642/tm2410009-1_4seq1.xml","form_type":"4"}},{"id":1558622,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2024-03-28T17:57:27.000Z","date":"2024-03-28","kind":"grant","planned":false,"acquired":true,"shares":6725,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and shall vest and be settled in the Issuer's common stock (\"Common Stock\") in three (3) equal annual installments beginning on March 28, 2025, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":331495,"source":{"system":"sec-edgar","filing":"0001104659-24-040642","document":"tm2410009-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465924040642/tm2410009-1_4seq1.xml","form_type":"4"}},{"id":1576976,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Tranche B Warrant","published_at":"2024-03-14T20:51:23.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price of the Tranche B Warrants is as follows:  1,000 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred."}],"balance_after":1000,"derivative":{"exercise_date":"2024-03-13","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001104659-24-034670","document":"tm248935-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465924034670/tm248935-1_4seq1.xml","form_type":"4"}},{"id":1576975,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Tranche A Warrant","published_at":"2024-03-14T20:51:23.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the Tranche A Warrants is as follows:  1,000 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred."}],"balance_after":1000,"derivative":{"exercise_date":"2024-03-13","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001104659-24-034670","document":"tm248935-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465924034670/tm248935-1_4seq1.xml","form_type":"4"}},{"id":1576974,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2024-03-14T20:51:23.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":7.29,"value":14580.0,"ownership":{"direct":true},"balance_after":324770,"source":{"system":"sec-edgar","filing":"0001104659-24-034670","document":"tm248935-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465924034670/tm248935-1_4seq1.xml","form_type":"4"}},{"id":1957053,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-03-13T18:30:51.000Z","date":"2023-03-09","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent of these options vest on March 9, 2024, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":16000,"derivative":{"exercise_price":5.08,"expiration_date":"2033-03-09","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001104659-23-031882","document":"tm239268d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465923031882/tm239268d1_4.xml","form_type":"4"}},{"id":1957052,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2023-03-13T18:30:51.000Z","date":"2022-08-23","kind":"exercise","acquired":false,"shares":604510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of Common Stock any time at the option of the holder thereof, subject to certain limitations. On August 23, 2022, the Reporting Person converted 604,510 shares of Series A Non-Voting Convertible Preferred Stock into 6,045,100 shares of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of Common Stock any time at the option of the holder thereof, subject to certain limitations. On August 23, 2022, the Reporting Person converted 604,510 shares of Series A Non-Voting Convertible Preferred Stock into 6,045,100 shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of Common Stock any time at the option of the holder thereof, subject to certain limitations. On August 23, 2022, the Reporting Person converted 604,510 shares of Series A Non-Voting Convertible Preferred Stock into 6,045,100 shares of Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6045100},"source":{"system":"sec-edgar","filing":"0001104659-23-031882","document":"tm239268d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465923031882/tm239268d1_4.xml","form_type":"4"}},{"id":1957051,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2023-03-13T18:30:51.000Z","date":"2023-03-09","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and shall vest and be settled in the Issuer's common stock (\"Common Stock\") in three (3) equal annual installments beginning on March 9, 2024 until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Reflects a one-for-20 reverse split, effective as of 5:00 p.m. Eastern Time on February 10, 2023."}],"balance_after":322770,"source":{"system":"sec-edgar","filing":"0001104659-23-031882","document":"tm239268d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465923031882/tm239268d1_4.xml","form_type":"4"}},{"id":1957050,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2023-03-13T18:30:51.000Z","date":"2022-08-23","kind":"exercise","acquired":true,"shares":6045100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of Common Stock any time at the option of the holder thereof, subject to certain limitations. On August 23, 2022, the Reporting Person converted 604,510 shares of Series A Non-Voting Convertible Preferred Stock into 6,045,100 shares of Common Stock."}],"balance_after":6375414,"source":{"system":"sec-edgar","filing":"0001104659-23-031882","document":"tm239268d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465923031882/tm239268d1_4.xml","form_type":"4"}},{"id":2199193,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Stock Option (right to Buy)","published_at":"2022-08-01T17:01:42.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":148700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of these options vest on July 28, 2023, with the remaining options vesting ratably over the following 36 months, subject to the\nreporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":148700,"derivative":{"exercise_price":1.09,"expiration_date":"2032-07-28","underlying":"Common Stock","underlying_shares":148700},"source":{"system":"sec-edgar","filing":"0001104659-22-084763","document":"tm2222147-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465922084763/tm2222147-3_4seq1.xml","form_type":"4"}},{"id":2199192,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":60681,"kind":"person","name":"Gilad Oren","position":1,"cik":"0001929300","reported_name":"Gilad Oren","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Common Stock","published_at":"2022-08-01T17:01:42.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":101300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock as follows: (i)\n33,766 shares on July 28, 2023, (ii) 33,767 shares on July 28, 2024 and (iii) 33,767 shares on July 28, 2025, subject to the reporting person's continued\nemployment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":330314,"source":{"system":"sec-edgar","filing":"0001104659-22-084763","document":"tm2222147-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1929300/000110465922084763/tm2222147-3_4seq1.xml","form_type":"4"}}]}